Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma

Eden Biltibo • 15 Apr 2024
EBMT 2024
Multiple Myeloma Antibodies CAR-T

Eden Biltibo, MD, Vanderbilt University Medical Center, Nashville, TN, discusses a study investigating the side effect profiles of commercially available bispecific antibodies and CAR T-cell therapies to treat multiple myeloma. Based on data from pivotal clinical trials, the analysis found that bispecific antibodies were associated with a shorter duration of cytokine release syndrome (CRS) and neurotoxicity. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

1:50
The recent expanded approval of cilta-cel into earlier lines of myeloma therapy
Roberto Mina • 23 Apr 2024
2:13
Frontline treatment of transplant eligible patients with myeloma: current approach & future changes
Karthik Ramasamy • 28 Apr 2024
History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals